RT Journal Article SR Electronic T1 Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey JF RMD Open JO RMD Open FD EULAR SP e001814 DO 10.1136/rmdopen-2021-001814 VO 7 IS 3 A1 Sebastian Eduardo Sattui A1 Jean W Liew A1 Kevin Kennedy A1 Emily Sirotich A1 Michael Putman A1 Tarin T Moni A1 Akpabio Akpabio A1 Deshiré Alpízar-Rodríguez A1 Francis Berenbaum A1 Inita Bulina A1 Richard Conway A1 Aman Dev Singh A1 Eimear Duff A1 Karen L Durrant A1 Tamer A Gheita A1 Catherine L Hill A1 Richard A Howard A1 Bimba F Hoyer A1 Evelyn Hsieh A1 Lina El Kibbi A1 Adam Kilian A1 Alfred Hyoungju Kim A1 David F L Liew A1 Chieh Lo A1 Bruce Miller A1 Serena Mingolla A1 Michal Nudel A1 Candace A Palmerlee A1 Jasvinder A Singh A1 Namrata Singh A1 Manuel Francisco Ugarte-Gil A1 John Wallace A1 Kristen J Young A1 Suleman Bhana A1 Wendy Costello A1 Rebecca Grainger A1 Pedro M Machado A1 Philip C Robinson A1 Paul Sufka A1 Zachary S Wallace A1 Jinoos Yazdany A1 Carly Harrison A1 Maggie Larché A1 Mitchell Levine A1 Gary Foster A1 Lehana Thabane A1 Lisa G Rider A1 Jonathan S Hausmann A1 Julia F Simard A1 Jeffrey A Sparks YR 2021 UL http://rmdopen.bmj.com/content/7/3/e001814.abstract AB Background We describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.Methods From 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.Results We analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.Conclusion Among adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.Data are available on reasonable request. Researchers interested in performing additional analyses from survey data are invited to submit proposals through the COVID-19 Global Rheumatology Alliance at rheum-covid.org. For approved projects, we will be able to provide summary tables and data analyses as requested. We do not currently have IRB approval to make the raw data available to other researchers.